GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vincerx Pharma VINC · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.02

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Net income

−$30.1m

FY2018FY2024

Free cash flow

−$26.1m

FY2018FY2024

Shareholders' equity

$2.7m

FY2018FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross profit−$1.1m−$915,000−$939,000−$340,000−$172,996−$172,996—
Research and development$15.5m$28.1m$52.2m$40.1m$7.1m——
Operating income−$31.5m−$42.6m−$68.7m−$62.7m−$10.7m−$45,000−$1,400
Net income−$30.1m−$40.2m−$65.4m−$39.3m−$10.7m−$54,000−$1,400
Diluted earnings per share-5.75-6.80-11.21-6.84-7.41-0.04—

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$8.0m$18.2m$59.3m$117.7m$63.2m$1,000$25,000
Cash and short-term investments$5.0m$12.8m$52.5m$111.5m$61.8m$684,708$25,000
Total liabilities$5.3m$7.0m$11.6m$17.4m$5.5m$44,000$1,000
Debt—$2.5m$3.4m$4.2m———
Shareholders' equity$2.7m$11.2m$47.7m$100.3m$25.4m−$44,000$24,000
Shares outstanding5m6m6m6m1m1m0m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−$26.1m−$40.5m−$59.6m−$33.4m−$2.3m−$34,999—
Capital spending———−$5.3m−$258,000−$258,000—
Free cash flow−$26.1m−$40.5m−$59.6m−$38.7m−$2.5m−$292,999—

Latest quarters

By quarter end

Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023
Revenue—$1.1m———$1.3m——
Gross profit—$534,000−$275,000−$270,000−$264,000$1.1m−$254,000−$249,000
Operating income−$3.3m−$8.8m−$7.8m−$7.4m−$7.5m−$5.5m−$10.3m−$11.7m
Net income−$5.0m−$8.0m−$7.8m−$1.8m−$12.4m−$5.0m−$9.7m−$11.2m
Diluted earnings per share-0.96-1.53-1.50-0.35-2.37-0.84-1.65-1.89
Cash from operations−$4.0m−$6.0m−$6.0m−$5.0m−$7.0m−$8.0m−$6.0m−$12.0m
Total assets$4.7m$8.0m$14.9m$21.5m$11.1m$18.2m$26.3m$35.3m
Cash and short-term investments$4.4m$5.0m$10.1m$16.4m$5.1m$12.8m$20.8m$27.4m
Debt——$1.3m$1.2m$1.2m$1.2m$1.1m$1.1m
Shareholders' equity$2.1m$2.7m$9.1m$15.4m−$622,000$11.2m$15.7m$24.1m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-20.5%270.6%—
Net income-8.5%254.1%—

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020
Price to earnings-0.0-0.0-0.0-0.2-0.3

Share price return

Finished calendar years

202520242023202220212020
Return-96%158%-20%-92%-46%99%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 28 Jan 2025
  • 1-to-1 reverse split · 24 Dec 2020

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.